The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, producing billions in sales , its intellectual property lapse created a deluge of generic competition , significantly eroding its dominance. While certain businesses may attempt to capitalize on related treatments , the pr